Stocks Health care URGN
NASDAQ · Health careUroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. brought in $250.3M of revenue over the twelve months to September 30, 2026, up 159.3% from a year earlier. It posted a net loss of $65.8M. In fiscal 2025 capital spending exceeded operating cash flow by $162.7M. At September 30, 2026 it held $85.6M in cash against $200M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about UroGen Pharma Ltd.
- Net worth
- UroGen Pharma Ltd. has a market value (market cap) of $1.2B at the latest share price, and shareholders' equity of -$125.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $109.8M (+21.4% year on year), with a net loss of $153.5M. Over the 12 months to September 30, 2026: revenue $250.3M, net loss $65.8M.
- Cash flow
- In fiscal 2025 operations used $162.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- UroGen Pharma Ltd.'s next report is expected around March 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What UroGen Pharma Ltd. does
UroGen Pharma Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker URGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $109.8M | -$153.5M | -$3.19 | -$162.7M |
| 2024 | $90.4M | -$126.9M | -$2.96 | -$97.1M |
| 2023 | $82.7M | -$102.2M | -$3.55 | -$76.6M |
| 2022 | $64.4M | -$109.8M | -$4.81 | -$87.8M |
| 2021 | $48M | -$110.8M | -$4.96 | -$85.6M |
| 2020 | $11.8M | -$128.5M | -$5.90 | -$107.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where URGN ranks in Health care
Latest SEC filings
What UroGen Pharma Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 224% to $89M versus the same quarter last year; diluted EPS -$0.03 versus -$0.69.
- November 4, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- August 20, 2026Other event 8-K
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 199% to $72.5M versus the same quarter last year; diluted EPS -$0.28 versus -$1.05.
- August 5, 2026
- June 23, 2026
- June 2, 2026Other event 8-K
Insider trades
What the people running UroGen Pharma Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $3M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 8, 2026 | Degnan ChrisChief Financial Officer | Exercised options | 4,483 | - |
| October 8, 2026 | Degnan ChrisChief Financial Officer | Sold | 2,202 | $80.8K |
| September 8, 2026 | Smith Jason DrewGeneral Counsel | Sold | 1,519 | $64.6K |
| September 8, 2026 | Schoenberg MarkChief Medical Officer | Sold | 871 | $37.4K |
| September 7, 2026 | Smith Jason DrewGeneral Counsel | Exercised options | 3,334 | - |
| September 7, 2026 | Schoenberg MarkChief Medical Officer | Exercised options | 1,667 | - |
| August 26, 2026 | Robinson James A. Jr.Director | Exercised options | 2,000 | - |
| August 20, 2026 | Schoenberg MarkChief Medical Officer | Sold | 60,677 | $2.9M |
Who owns URGN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RTW Investments, LP13G, passive with 1 related filers | 9.99% | November 14, 2024 |
| BlackRock, Inc.13G, passive | 6.3% | October 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 189 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Rtw Investments, LP | 4,543,895 | 0 |
| BlackRock, Inc. | 3,201,461 | +355,894 |
| Morgan Stanley | 2,576,363 | +16,325 |
| Kynam Capital Management, LP | 2,434,207 | +186,814 |
| Jefferies Financial Group Inc. | 2,199,652 | 0 |
| American Century Companies Inc | 1,685,719 | +48,149 |
| Acorn Capital Advisors, LLC | 1,673,420 | 0 |
| Point72 Asset Management, L.P. | 1,525,549 | new |
| Frontier Capital Management Co LLC | 1,508,547 | +194,435 |
| Opaleye Management Inc. | 1,439,996 | +9,996 |
| Silverarc Capital Management, LLC | 1,301,979 | -201,066 |
| Menora Mivtachim Holdings Ltd. | 1,152,531 | 0 |
| D. E. Shaw & Co., Inc. | 1,145,819 | +122,660 |
| State Street Corp | 1,003,071 | +128,895 |
| Mpm Bioimpact LLC | 933,415 | -10,388 |
| Soleus Capital Management, L.P. | 829,810 | +102,810 |
| Goldman Sachs Group Inc | 819,834 | +221,306 |
| Migdal Insurance & Financial Holdings Ltd. | 770,909 | 0 |
| Orbimed Advisors LLC | 676,187 | -199,300 |
| Geode Capital Management, LLC | 610,364 | +86,533 |
Insiders
8 insiders reported holding 192,670 shares in total, about $4.9M at the last price.
| Holder | Shares |
|---|---|
| Schoenberg MarkChief Medical Officer | 118,968 |
| Smith Jason DrewGeneral Counsel | 53,141 |
| Robinson James A. Jr.Director | 8,000 |
| Degnan ChrisChief Financial Officer | 4,561 |
| Wildman Daniel GeorgeDirector | 2,000 |
| Holden StuartDirector | 2,000 |
| Wen LeanaDirector | 2,000 |
| Butitta Cynthia MDirector | 2,000 |
Questions about URGN
What does UroGen Pharma Ltd. do?
UroGen Pharma Ltd. is a company in the Health care sector, listed on NASDAQ as URGN. Its shares trade on NASDAQ under the ticker URGN.
What is UroGen Pharma Ltd.'s net worth?
UroGen Pharma Ltd. has a market value (market cap) of $1.2B at the latest share price, and shareholders' equity of -$125.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is UroGen Pharma Ltd. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $65.8M on revenue of $250.3M.
How much revenue does UroGen Pharma Ltd. make?
Over the twelve months to September 30, 2026 UroGen Pharma Ltd. reported revenue of $250.3M. That is 159.3% more than a year earlier.
When did UroGen Pharma Ltd. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is UroGen Pharma Ltd.'s next earnings report?
UroGen Pharma Ltd.'s next report is expected around March 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare URGN with
Follow URGN
Get an email when UroGen Pharma Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values UroGen Pharma Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.